Literature DB >> 26271312

Levels of F2-isoprostanes, F4-neuroprostanes, and total nitrate/nitrite in plasma and cerebrospinal fluid of patients with traumatic brain injury.

H-C Yen1, T-W Chen1, T-C Yang2, H-J Wei1, J-C Hsu3, C-L Lin2.   

Abstract

Several events occurring during the secondary damage of traumatic brain injury (TBI) can cause oxidative stress. F(2)-isoprostanes (F(2)-IsoPs) and F(4)-neuroprostanes (F(4)-NPs) are specific lipid peroxidation markers generated from arachidonic acid and docosahexaenoic acid, respectively. In this study, we evaluated oxidative stress in patients with moderate and severe TBI. Since sedatives are routinely used to treat TBI patients and propofol has been considered an antioxidant, TBI patients were randomly treated with propofol or midazolam for 72 h postoperation. We postoperatively collected cerebrospinal fluid (CSF) and plasma from 15 TBI patients for 6-10 d and a single specimen of CSF or plasma from 11 controls. Compared with the controls, the TBI patients exhibited elevated levels of F(2)-IsoPs and F(4)-NPs in CSF throughout the postsurgery period regardless of the sedative used. Compared with the group of patients who received midazolam, those who received propofol exhibited markedly augmented levels of plasma F(2)-IsoPs, which were associated with higher F(4)-NPs levels and lower total nitrate/nitrite levels in CSF early in the postsurgery period. Furthermore, the higher CSF F(2)-IsoPs levels correlated with 6-month and 12-month worse outcomes, which were graded according to the Glasgow Outcome Scale. The results demonstrate enhanced oxidative damage in the brain of TBI patients and the association of higher CSF levels of F(2)-IsoPs with a poor outcome. Moreover, propofol treatment might promote lipid peroxidation in the circulation, despite possibly suppressing nitric oxide or peroxynitrite levels in CSF, because of the increased loading of the lipid components from the propofol infusion.

Entities:  

Keywords:  head injury; lipid peroxidation; nitric oxide; outcome; sedative

Mesh:

Substances:

Year:  2015        PMID: 26271312     DOI: 10.3109/10715762.2015.1080363

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  8 in total

1.  Role of CAPE in reducing oxidative stress in animal models with traumatic brain injury.

Authors:  Rizha Anshori Nasution; Andi Asadul Islam; Mochammad Hatta; Agus Turchan; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2020-07-22

Review 2.  Chronic cerebrovascular dysfunction after traumatic brain injury.

Authors:  Amandine Jullienne; Andre Obenaus; Aleksandra Ichkova; Catherine Savona-Baron; William J Pearce; Jerome Badaut
Journal:  J Neurosci Res       Date:  2016-04-27       Impact factor: 4.164

Review 3.  Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury.

Authors:  Clifford L Eastman; Raimondo D'Ambrosio; Thota Ganesh
Journal:  Neuropharmacology       Date:  2019-12-06       Impact factor: 5.250

Review 4.  Targeting NRF2 to suppress ferroptosis in brain injury.

Authors:  Shunchen Song; Yaxuan Gao; Yi Sheng; Tongyu Rui; Chengliang Luo
Journal:  Histol Histopathol       Date:  2020-11-26       Impact factor: 2.303

Review 5.  Oxidized phospholipid signaling in traumatic brain injury.

Authors:  Tamil S Anthonymuthu; Elizabeth M Kenny; Andrew M Lamade; Valerian E Kagan; Hülya Bayır
Journal:  Free Radic Biol Med       Date:  2018-06-30       Impact factor: 7.376

Review 6.  Lipoxidation in cardiovascular diseases.

Authors:  Erica Gianazza; Maura Brioschi; Alma Martinez Fernandez; Cristina Banfi
Journal:  Redox Biol       Date:  2019-02-25       Impact factor: 11.799

7.  Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease.

Authors:  Cinzia Signorini; Claudio De Felice; Thierry Durand; Jean-Marie Galano; Camille Oger; Silvia Leoncini; Joussef Hayek; Jetty Chung-Yung Lee; Troy C Lund; Paul J Orchard
Journal:  Life (Basel)       Date:  2022-01-20

Review 8.  Isoprostanoids in Clinical and Experimental Neurological Disease Models.

Authors:  Cinzia Signorini; Claudio De Felice; Jean-Marie Galano; Camille Oger; Silvia Leoncini; Alessio Cortelazzo; Lucia Ciccoli; Thierry Durand; Joussef Hayek; Jetty Chung-Yung Lee
Journal:  Antioxidants (Basel)       Date:  2018-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.